ASEAN Cancer Targeted Therapy Market Report Outlook (2021–2031)

Recent Advances in Genomic Profiling and Biomarker Discovery

The ASEAN cancer targeted therapy market is primarily driven by advancements in genomic profiling and biomarker discovery, which are enabling precision oncology adoption across the region. Next-generation sequencing (NGS), liquid biopsy technologies, and molecular diagnostics allow clinicians to detect actionable genetic alterations such as EGFR, ALK, BRAF, RET, and PIK3CA mutations with high precision. These biomarkers guide therapy selection, improving patient outcomes, reducing adverse events, and minimizing unnecessary chemotherapy exposure. Countries such as Singapore, Malaysia, and Thailand have invested heavily in central genomic testing networks and integrated diagnostic pathways, enabling the timely identification of patients eligible for targeted therapies. Public and private reimbursement programs are gradually expanding, reducing cost barriers, and widening access. Regional clinical trials increasingly leverage molecular profiling to match patients to precision therapies, accelerating drug development and regulatory approvals. Artificial intelligence and bioinformatics tools are strengthening biomarker validation, resistance profiling, and personalized treatment strategies. The proliferation of regional genomic databases and collaborative networks further supports real-world evidence generation, informing treatment guidelines and reimbursement policies. Collectively, these factors create an enabling ecosystem for precision oncology in ASEAN, driving the adoption of monoclonal antibodies, immune checkpoint inhibitors, and tyrosine kinase inhibitors, while contributing to sustained market growth.

Expanding Targeted Therapies for Rare Genetically Driven Cancers

The ASEAN cancer targeted therapy market presents significant opportunities in expanding treatments into rare cancers and genetically defined tumor subtypes. Advances in genomic sequencing and biomarker testing have revealed that several rare and low-incidence cancers harbor actionable mutations, making mutation-driven therapies commercially viable across multiple indications. Tumor-agnostic approaches targeting NTRK fusions, RET rearrangements, FGFR alterations, and BRAF mutations allow pharmaceutical companies to broaden indications for a single therapy across diverse malignancies. Regional regulatory frameworks—including orphan drug pathways and conditional approvals—support faster market entry and extended exclusivity for rare cancer therapies. ASEAN countries are increasingly adopting basket and umbrella trial designs to accelerate clinical development timelines while optimizing patient enrollment.

Access to comprehensive molecular testing has improved the detection of rare mutations in Indonesia, Malaysia, and Vietnam, expanding the addressable patient population. Growing integration of precision medicine into treatment guidelines across Singapore and Thailand encourages the adoption of targeted therapies for rare indications. Partnerships between multinational pharmaceutical companies and regional research institutions further enable pipeline expansion and clinical trial support. As awareness of molecularly guided treatments rises among healthcare providers and patients, market penetration for niche therapies is expected to grow rapidly. These factors collectively represent a strategic opportunity for companies to invest in rare cancer therapeutics and leverage ASEAN's diverse population to strengthen long-term revenue streams, while advancing precision oncology in the region.

The "ASEAN Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• ASEAN Cancer Targeted Therapy market size and forecast at regional and country levels for key market segments covered under the scope
• ASEAN Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• ASEAN Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the ASEAN Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the ASEAN Cancer Targeted Therapy market report is divided into: Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. Singapore held the largest share in 2024.

The ASEAN cancer targeted therapy market exhibits diverse adoption patterns shaped by healthcare infrastructure, government initiatives, and private sector engagement. Singapore leads the region with advanced hospitals, strong insurance coverage, and centralized oncology networks, enabling rapid adoption of monoclonal antibodies, immune checkpoint inhibitors, and tyrosine kinase inhibitors. Malaysia benefits from public-private partnerships, extensive molecular testing adoption, and supportive government policies promoting precision oncology. Thailand demonstrates strong growth through participation in international clinical trials, national cancer programs, and investments in genomic testing infrastructure. Indonesia and Vietnam are emerging markets, experiencing incremental uptake due to the gradual expansion of oncology centers, increasing awareness of precision therapies, and cost-sensitive healthcare models.

Across the region, hospitals remain the dominant end users. Specialty oncology centers and private clinics are increasingly investing in targeted therapies and diagnostic capabilities. Variations in reimbursement coverage, affordability, and infrastructure maturity influence adoption rates, requiring tailored market strategies. Singapore and Thailand focus on high-end precision oncology and early access programs, whereas Indonesia and Vietnam emphasize accessibility and partnership-driven adoption models. ASEAN's country-level dynamics underscore a balance between mature markets with rapid adoption of cutting-edge therapies and developing markets with incremental growth, offering significant opportunities for pharmaceutical companies to expand their regional presence, strengthen partnerships, and leverage genomic and clinical trial networks for sustainable growth in cancer targeted therapies.

• The report includes qualitative and quantitative data in the ASEAN Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the ASEAN Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the ASEAN Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the ASEAN Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover ASEAN Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The ASEAN Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the ASEAN cancer targeted therapy market are:

• In March 2025, Singapore‑based EBD Biosciences began a Phase 2 clinical trial of a bispecific antibody designed to target EGFR and PD‑L1 in patients with non‑small cell lung cancer. This approach is particularly relevant in Asia, where EGFR mutations are common drivers of lung cancer, and PD‑L1 blockade has become a cornerstone of immunotherapy.
• In February 2025, Indonesia's Kalbe Farma initiated an early‑stage clinical trial for a novel FGFR inhibitor. This drug is being developed to treat cholangiocarcinoma, a bile duct cancer with high incidence in Southeast Asia, as well as other rare cancers driven by FGFR genetic alterations.